Reshaping Research Framework to Enhance the Ability to Generate Innovative Drugs
Tokyo, Japan, May 14, 2013 - Astellas Pharma Inc. (Tokyo:4503, President and CEO: Yoshihiko Hatanaka, hereinafter called "Astellas") today announced plans to reshape its research framework by introducing new initiatives to further enhance the ability to generate innovative drugs...
Optimize research functions
The reshaping initiatives outlined below will be carried out to reallocate resources and realize operational excellence.
? Close/scale back research functions
(Scheduled during FY2013: Some functions are scheduled for transfer to the Tsukuba Research Center)
·OSI Pharmaceuticals, LLC (US): To be closed
·Perseid Therapeutics LLC (US): To be closed
·Astellas Research Institute of America LLC (US): To be scaled back (focus on CNS therapies)
? Cease in-house fermentation research
? Close the Kashima facility in Osaka (scheduled during FY2015)